Compare Adaptive Biotechnologies Corp (ADPT) vs IQIYI Inc - ADR (IQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs IQIYI Inc - ADR — how do they compare? Adaptive Biotechnologies Corp trades at $19.96 (market cap $3.33B), while IQIYI Inc - ADR trades at $1.06 (market cap $960.59M). The key difference: Adaptive Biotechnologies Corp is far larger — about 3.5× IQIYI Inc - ADR's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, IQIYI Inc - ADR nearer its low. Which is the better fit depends on your goals.
| ADPT | IQ | |
|---|---|---|
Market Cap | $3.33B | $960.59M |
Sector | Health | Media |
52-Week High | $22.37 | $2.79 |
52-Week Low | $10.24 | $0.96 |
Enterprise Value | $3.19B | $2.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
iQIYI (IQ) trades at $0.9954, down 1.45% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $206.31 million in 2025 despite $27.29 billion in revenue, with negative profit margins and declining revenue trends. Recent news highlights leadership changes and AI platform expansion, but financial performance remains pressured.
The outlook is mixed: analyst consensus leans bullish with 50% buy ratings, but fundamental weakness and cash flow volatility pose risks. Investment opportunity hinges on AI-driven turnaround execution, while key risks include sustained profitability challenges and competitive pressures in China's streaming market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →
